The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.

ABSTRACT:

SUBMITTER: O'Sullivan JM 

PROVIDER: S-EPMC6917505 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature